Evidence map›Paper›PMID 24714398›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2014

Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.

Kiichiro Ueta, Tracy P O'Brien, Gregory A McCoy, Kuikwon Kim, Erin C Healey, Tiffany D Farmer, E Patrick Donahue, Audree B Condren, Richard L Printz, Masakazu Shiota

Abstract read
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Journal of agricultural and food chemistry · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kiichiro UetaDepartment of Molecular Physiology and Biophysics and.
Tracy P O'BrienDepartment of Molecular Physiology and Biophysics and.
Gregory A McCoyDepartment of Molecular Physiology and Biophysics and.
Kuikwon KimDepartment of Molecular Physiology and Biophysics and.
Erin C HealeyDepartment of Molecular Physiology and Biophysics and.
Tiffany D FarmerDiabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
E Patrick DonahueDiabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Audree B CondrenDepartment of Molecular Physiology and Biophysics and.
Richard L PrintzDepartment of Molecular Physiology and Biophysics and Diabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Masakazu ShiotaDepartment of Molecular Physiology and Biophysics and Diabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee masakazu.shiota@Vanderbilt.edu.
Vanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI MCGUINNESS, OWEN P · 1986 to 2011
$28.1M
Liver Glucose Flux in Obesity and DiabetesR01DK060667 · NIDDK · VANDERBILT UNIVERSITY · PI SHIOTA, MASAKAZU · 2002 to 2016
$4.0M
Liver glucose Flux in Obesity and DiabetesR56DK060667 · NIDDK · VANDERBILT UNIVERSITY · PI SHIOTA, MASAKAZU · 2007 to 2007
$282k
NCI NIH HHS CA-68485NIDDK NIH HHS DK-20593NIDDK NIH HHS DK-60667NIDDK NIH HHS P30 DK020593NIDDK NIH HHS R01 DK060667
6 · The paper itself

Abstract

A loss of glucose effectiveness to suppress hepatic glucose production as well as increase hepatic glucose uptake and storage as glycogen is associated with a defective increase in glucose phosphorylation catalyzed by glucokinase (GK) in Zucker diabetic fatty (ZDF) rats. We extended these observations by investigating the role of persistent hyperglycemia (glucotoxicity) in the development of impaired hepatic GK activity in ZDF rats. We measured expression and localization of GK and GK regulatory protein (GKRP), translocation of GK, and hepatic glucose flux in response to a gastric mixed meal load (MMT) and hyperglycemic hyperinsulinemic clamp after 1 or 6 wk of treatment with the sodium-glucose transporter 2 inhibitor (canaglifrozin) that was used to correct the persistent hyperglycemia of ZDF rats. Defective augmentation of glucose phosphorylation in response to a rise in plasma glucose in ZDF rats was associated with the coresidency of GKRP with GK in the cytoplasm in the midstage of diabetes, which was followed by a decrease in GK protein levels due to impaired posttranscriptional processing in the late stage of diabetes. Correcting hyperglycemia from the middle diabetic stage normalized the rate of glucose phosphorylation by maintaining GK protein levels, restoring normal nuclear residency of GK and GKRP under basal conditions and normalizing translocation of GK from the nucleus to the cytoplasm, with GKRP remaining in the nucleus in response to a rise in plasma glucose. This improved the liver's metabolic ability to respond to hyperglycemic hyperinsulinemia. Glucotoxicity is responsible for loss of glucose effectiveness and is associated with altered GK regulation in the ZDF rat.

Indexed as

AnimalsBody WeightCanagliflozinDiabetes Mellitus, Type 2EatingGlucagonGlucokinaseGlucoseGlucose Clamp TechniqueGlucosidesHyperglycemiaHyperinsulinismImmunohistochemistryLiverMaleObesityCanagliflozinGlucagonGlucokinaseGlucoseGlucosidesRNA, MessengerSlc5a2 protein, ratSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsThiophenesglucokinaseglucotoxicityhepatic glucose fluxsodium-glucose cotransporter 2 inhibitortype 2 diabetes

Identifiers

PMID24714398
PMCPMC4042096
OpenAlexW2156066074

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.